83-5963-41　Abciximab Biosimilar, Glycoprotein IIb/IIIa Receptor 100ug　591640

特徴

• Abciximab Biosimilar uses the same protein sequences as the therapeutic antibody abciximab.
• Abciximab, a glycoprotein IIb/IIIa receptor antagonist, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery.
• It is a glycoprotein IIb/IIIa inhibitor.
• While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks.
• In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.
• Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
• Applications:Suitable for use in ELISA, Neutralization, Functional Assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Abciximab.
• Other applications not tested.
• Recommended Dilution:Optimal dilutions to be determined by the researcher.
• Storage and Stability:May be stored at 4℃ for short-term only.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20℃.
• Aliquots are stable for 12 months after receipt.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.